Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 70.39M.
Subavaliada
O PE mais recente da empresa é -4.01, em uma faixa percentil baixa de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 66.34M ações, uma redução de 17.31% em relação ao trimestre anterior.
Mantido por ETHSX
O Super Investidor ETHSX possui 210.50K ações desta empresa.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 0.24.